• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Imaging and Intervention

Radiotherapy alone noninferior to concurrent chemoradiotherapy survival without disease relapse in patients with low-risk nasopharyngeal carcinoma

byGursharan SohiandYuchen Dai
August 28, 2022
in Imaging and Intervention, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with low-risk nasopharyngeal carcinoma did not have significantly different disease-free survival rates whether they received radiotherapy alone or with concurrent chemoradiotherapy.

2. Patients in the radiotherapy alone group experienced significantly fewer serious adverse events compared to patients receiving concurrent chemoradiotherapy

Level of Evidence Rating: 1 (Excellent)

Study Rundown: The current standard of care for management of stage II nasopharyngeal carcinoma is radiotherapy with concurrent chemotherapy, typically using a cisplatin-based agent. However, this treatment is fraught with a high risk of adverse events, weight loss and poor oncologic outcomes. Observational studies in recent years have determined that patients treated with radiotherapy alone have good survival outcomes, but this has never been compared head-to-head with concurrent chemotherapy. The present study by Tang et al randomized patients with stage II nasopharyngeal carcinoma to receiving radiation alone or chemoradiation to assess for differences in survival outcomes.

A total of 341 individuals participated in this trial, including 172 in the radiation group and 169 in the chemoradiation group. Baseline characteristics were well-balanced between the two groups. 95.9% of the radiation participants completed their complete treatment as defined by the protocol while only 60.4% of the chemoradiation group received all three rounds of chemotherapy and radiation. With a median follow-up time of 46 months, the locoregional failure rate was not different in the radiation (7.6%) versus chemoradiation (6.5%) groups, nor was the 3-year disease-free survival rate (90.5% vs. 91.9%). There were significantly fewer grade 3 or 4 adverse events reported amongst patients receiving radiation only in comparison to those who received chemotherapy.

This randomized controlled trial published by Tang et al demonstrated noninferior disease-free survival outcomes amongst patients with stage II nasopharyngeal carcinoma receiving radiation only compared to those receiving radiation with concurrent chemotherapy. These findings may influence practice and reduce the rate of serious adverse events experienced by patients with nasopharyngeal cancer in future. The conclusions reported here are strengthened by the randomized nature of this work which did well to control for confounding. However, these findings may be specific to the healthcare system and patient population in China, and therefore should be interpreted with clinical context in mind.

Click here to read this study in JAMA

RELATED REPORTS

#VisualAbstract: Adjuvant capecitabine improves clinical outcomes in patients with locally advanced nasopharyngeal carcinoma

#VisualAbstract: Intensity-modulated radiotherapy alone is noninferior to concurrent chemoradiotherapy for low-risk nasopharyngeal carcinoma

#VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma

Relevant reading: Nasopharyngeal carcinoma

In Depth [randomized controlled trial]: A multi-center, parallel group randomized controlled trial was conducted in China. Patients with stage II and T3N0M0 nasopharyngeal cancer who were between 18 and 65 years, had a Karnofsky performance status greater than 70 and met specific hematological parameters were included. Randomization was performed by a computer program using blocks of 4. Patients receiving chemotherapy were administered cisplatin at 100mg/m2 for 3 cycles of 3 weeks each, concurrent to radiotherapy. The radiation protocol consisted of 68-70 Gy administered using guideline-specified practices.

The locoregional failure rate was 7.6% in the radiation group and 6.5% in the chemoradiation group (p =0.71), which was not significantly different. The 3-year disease-free survival was 90.5% in the radiation group and 91.9% in the chemoradiation group (p < 0.001). The absolute rate difference was 1.4% with a one-sided 95% confidence interval -7.4% to infinity. The hazard ratio for this outcome was 1.36 (0.70-2.66). The rate of serious adverse events reported in the radiotherapy group was 17% versus 46% in the chemoradiotherapy group (p<0.001). There was a significantly lower rate of the following adverse events in the radiation-only group specifically: leukopenia (1% vs 10%), neutropenia (2% vs 7%), nausea (1% vs 13%), vomiting (1% vs 15%), anorexia (5% vs 29%), weight loss (1%) vs 5%), and mucositis (10% vs 19%).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: concurrent chemoradiotherapynasopharyngeal carcinomanoninferiorityradiotherapy
Previous Post

Statin use provide effective primary prevention against cardiovascular disease in high-risk patients – US Preventive Services Task Force

Next Post

2 Minute Medicine Rewind August 29, 2022

RelatedReports

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves clinical outcomes in patients with locally advanced nasopharyngeal carcinoma

January 25, 2023
#VisualAbstract: Intensity-modulated radiotherapy alone is noninferior to concurrent chemoradiotherapy for low-risk nasopharyngeal carcinoma
StudyGraphics

#VisualAbstract: Intensity-modulated radiotherapy alone is noninferior to concurrent chemoradiotherapy for low-risk nasopharyngeal carcinoma

October 25, 2022
#VisualAbstract: Induction chemotherapy with cisplatin plus  gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma
StudyGraphics

#VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma

September 20, 2022
2 Minute Medicine Rewind January 28, 2019
Chronic Disease

Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis

August 26, 2022
Next Post
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males

2 Minute Medicine Rewind August 29, 2022

Increased risk of stillbirth recurrence after a previous stillbirth

Patients' concept of dignity may help direct end-of-life care

Increased risk of subsequent melanoma after first melanoma diagnosis

Talimogene laherparepvec addition to pembrolizumab showed no significant clinical improvement in advanced melanoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options